Similar articles for PMID: 26598453

Year	Number of Results
1981	1
1983	1
1984	4
1985	2
1986	1
1987	2
1988	3
1989	2
1990	3
1991	1
1992	4
1993	5
1994	1
1998	3
1999	4
2000	2
2001	4
2002	3
2003	4
2004	3
2005	4
2006	9
2007	12
2008	6
2009	8
2010	7
2011	6
2012	19
2013	24
2014	28
2015	33
2016	30
2017	31
2018	20
2019	13
2020	21
2021	20

1

FDA Safety Reviews on Drugs, Biologics, and Vaccines: 2007-2013.

Cope JU, Rosenthal GL, Weinel P, Odegaard A, Murphy DM. Cope JU, et al. Pediatrics. 2015 Dec;136(6):1125-31. doi: 10.1542/peds.2015-0469. Pediatrics. 2015. PMID: 26598453 Review.

2

Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.

Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, Braun MM, Chen RT. Zhou W, et al. MMWR Surveill Summ. 2003 Jan 24;52(1):1-24. MMWR Surveill Summ. 2003. PMID: 12825543 Free article.

3

Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database.

Beninger P, Murray M. Beninger P, et al. Clin Ther. 2021 Feb;43(2):380-395. doi: 10.1016/j.clinthera.2020.12.011. Epub 2021 Jan 24. Clin Ther. 2021. PMID: 33504449

4

FDA working to ensure the safety of medical devices used in the pediatric population.

Flack MN, Gross TP, Reid JS, Mills TT, Francis J. Flack MN, et al. Pediatr Clin North Am. 2012 Dec;59(6):1355-66. doi: 10.1016/j.pcl.2012.08.003. Epub 2012 Oct 13. Pediatr Clin North Am. 2012. PMID: 23116531

5

FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.

Roller ST, Pippins RR, Ngai JW. Roller ST, et al. Food Drug Law J. 2009;64(3):577-98. Food Drug Law J. 2009. PMID: 19999646

6

The FDA and drug safety: a proposal for sweeping changes.

Furberg CD, Levin AA, Gross PA, Shapiro RS, Strom BL. Furberg CD, et al. Arch Intern Med. 2006 Oct 9;166(18):1938-42. doi: 10.1001/archinte.166.18.1938. Arch Intern Med. 2006. PMID: 17030825

7

Food and Drug Administration (FDA) postmarket reported side effects and adverse events associated with pulmonary hypertension therapy in pediatric patients.

Maxey DM, Ivy DD, Ogawa MT, Feinstein JA. Maxey DM, et al. Pediatr Cardiol. 2013 Oct;34(7):1628-36. doi: 10.1007/s00246-013-0688-2. Epub 2013 Mar 27. Pediatr Cardiol. 2013. PMID: 23532466 Free PMC article.

8

Pediatric post-marketing safety systems in North America: assessment of the current status.

McMahon AW, Wharton GT, Bonnel R, DeCelle M, Swank K, Testoni D, Cope JU, Smith PB, Wu E, Murphy MD. McMahon AW, et al. Pharmacoepidemiol Drug Saf. 2015 Aug;24(8):785-92. doi: 10.1002/pds.3813. Epub 2015 Jun 22. Pharmacoepidemiol Drug Saf. 2015. PMID: 26098297 Review.

9

A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes.

Hoffman KB, Dimbil M, Kyle RF, Tatonetti NP, Erdman CB, Demakas A, Chen D, Overstreet BM. Hoffman KB, et al. J Manag Care Spec Pharm. 2015 Dec;21(12):1134-43. doi: 10.18553/jmcp.2015.21.12.1134. J Manag Care Spec Pharm. 2015. PMID: 26679963

10

Post-licensure rapid immunization safety monitoring program (PRISM) data characterization.

Baker MA, Nguyen M, Cole DV, Lee GM, Lieu TA. Baker MA, et al. Vaccine. 2013 Dec 30;31 Suppl 10:K98-112. doi: 10.1016/j.vaccine.2013.04.088. Vaccine. 2013. PMID: 24331080

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed